
-
vTv Therapeutics NasdaqCM:VTVT vTv Therapeutics Inc., a clinical stage biopharmaceutical company, focuses on the development of orally administered treatments for metabolic and inflammatory diseases. The company's lead drug candidate is cadisegliatin (TTP399), an orally administered small molecule and liver-selective glucokinase activator that is in Phase III clinical trial to treat type 1 diabetes; and TTP273, an orally available small molecule glucagon-like peptide 1 receptor agonists that is in Phase I clinical trial for the treatment of postprandial hyperglycemia in cystic fibrosis related diabetes patients, as well as in Phase II trial for the treatment of type 2 diabetes. It is also developing HPP737, an orally administered non- central nervous system penetrant PDE4 inhibitor that has completed Phase 1 trials for the treatment of inflammatory diseases. In addition, the company's other programs include HPP3033, a non-electrophilic therapeutic approach to activating the nuclear factor erythroid 2related factor 2 (Nrf2) pathway for the treatment of chronic diseases associated with oxidative stress. It has a license agreement Newsoara Biopharma Co., Ltd. o develop and commercialize phosphodiesterase type 4 inhibitors program, including the compound HPP737. The company was incorporated in 2015 and is headquartered in High Point, North Carolina. vTv Therapeutics Inc. is a subsidiary of MacAndrews & Forbes Group LLC.
Location: 3980 Premier Drive, Suite 310, High Point, NC, 27265, United States | Website: https://vtvtherapeutics.com | Industry: Biotechnology | Sector: Healthcare
Market Cap
NaN
52 Wk Range
$ - $
Previous Close
$N/A
Open
$N/A
Day Range
N/A - N/A
Volume
N/A
Avg Volume
N/A
Enterprise Value
12.86M
Cash
31.06M
Avg Qtr Burn
-5.915M
Short % of Float
1.16%
Insider Ownership
35.60%
Institutional Own.
22.05%
Qtr Updated
03/31/25
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Cadisegliatin (TTP399) Details Type 1 diabetes, Diabetes | Phase 3 Update | |
HPP737 Details Psoriasis, Skin disease/disorder | Phase 2 Update | |
Cadisegliatin (TTP399) Details Diabetes, Type 2 diabetes | Phase 2 Initiation | |
TTP273 (Oral GLP-1R) Details Diabetes, Type 2 diabetes, Cystic fibrosis | Phase 1/2 Update | |
TTP488 (Azeliragon) (RAGE) Details Frontotemporal dementia with C9orf72 mutation, Dementia, Alzheimer's disease, Neurological disorder | Failed Discontinued |